ES2320699T3 - Derivados de azabiciclo(3.1.0)hexilfelino como moduladores de receptores d3 de dopamina. - Google Patents

Derivados de azabiciclo(3.1.0)hexilfelino como moduladores de receptores d3 de dopamina. Download PDF

Info

Publication number
ES2320699T3
ES2320699T3 ES06791595T ES06791595T ES2320699T3 ES 2320699 T3 ES2320699 T3 ES 2320699T3 ES 06791595 T ES06791595 T ES 06791595T ES 06791595 T ES06791595 T ES 06791595T ES 2320699 T3 ES2320699 T3 ES 2320699T3
Authority
ES
Spain
Prior art keywords
formula
compound
phenyl
azabicyclo
baselineskip
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES06791595T
Other languages
English (en)
Spanish (es)
Inventor
Gabriella Gentile
Dieter Hamprecht
Fabrizio Micheli
Adolfo Prandi
Silvia Terreni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ES2320699T3 publication Critical patent/ES2320699T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES06791595T 2005-08-22 2006-08-18 Derivados de azabiciclo(3.1.0)hexilfelino como moduladores de receptores d3 de dopamina. Expired - Lifetime ES2320699T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0517175.6A GB0517175D0 (en) 2005-08-22 2005-08-22 Compounds
GB0517175 2005-08-22

Publications (1)

Publication Number Publication Date
ES2320699T3 true ES2320699T3 (es) 2009-05-27

Family

ID=35098086

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06791595T Expired - Lifetime ES2320699T3 (es) 2005-08-22 2006-08-18 Derivados de azabiciclo(3.1.0)hexilfelino como moduladores de receptores d3 de dopamina.

Country Status (8)

Country Link
US (1) US7776904B2 (enExample)
EP (1) EP1917242B1 (enExample)
JP (1) JP5084731B2 (enExample)
AT (1) ATE420859T1 (enExample)
DE (1) DE602006004882D1 (enExample)
ES (1) ES2320699T3 (enExample)
GB (1) GB0517175D0 (enExample)
WO (1) WO2007022935A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE451364T1 (de) * 2004-02-23 2009-12-15 Glaxo Group Ltd Als modulatoren des dopamin-d3-rezeptors geeignete azabicycloä3.1.0ühexanderivate
GB0507601D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507602D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
JP5068747B2 (ja) * 2005-06-14 2012-11-07 グラクソ グループ リミテッド ドーパミンｄ３受容体のモジュレーターとしてのアザビシクロ［３．１．０］ヘキサン誘導体
GB0512099D0 (en) * 2005-06-14 2005-07-20 Glaxo Group Ltd Compounds
ZA200801825B (en) 2005-07-27 2009-12-30 Dov Pharmaceutical Inc Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: Preparation and use to treat neuropsychiatric disorders
GB0517193D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Novel use
ATE487715T1 (de) * 2005-08-22 2010-11-15 Glaxo Group Ltd Triazolderivate als modulatoren von dopamin-d3- rezeptoren
GB0517187D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517191D0 (en) 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
ATE498619T1 (de) * 2006-04-03 2011-03-15 Glaxo Group Ltd Azabicycloä3.1.0ühexanderivate als modulatoren von dopamin-d3-rezeptoren
US8222266B2 (en) * 2006-04-03 2012-07-17 Glaxo Group Limited Azabicyclo [3.1.0] hexyl derivatives as modulators of dopamine D3 receptors
RU2012102094A (ru) 2009-06-26 2013-08-10 Панацеа Биотек Лтд. Новые азабициклогексаны
US20140206740A1 (en) 2011-07-30 2014-07-24 Neurovance, Inc. Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
KR102359707B1 (ko) 2016-07-20 2022-02-09 노파르티스 아게 아미노피리딘 유도체 및 이의 선택적 alk-2 억제제로서의 용도
CN108997177A (zh) * 2018-09-04 2018-12-14 邵阳学院 一种微波促进n-苯磺酰基硝基苯胺类化合物合成的方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL65843A (en) * 1977-08-11 1986-12-31 American Cyanamid Co Pharmaceutical compositions for the treatment of depression containing 3-aza-bicyclo(3.1.0)hexane derivatives and certain novel compounds of this type
US4435419A (en) 1981-07-01 1984-03-06 American Cyanamid Company Method of treating depression using azabicyclohexanes
US6204284B1 (en) * 1991-12-20 2001-03-20 American Cyanamid Company Use of 1-(substitutedphenyl)-3-azabicyclo[3.1.0]hexanes for the treatment of chemical dependencies
ATE451364T1 (de) 2004-02-23 2009-12-15 Glaxo Group Ltd Als modulatoren des dopamin-d3-rezeptors geeignete azabicycloä3.1.0ühexanderivate
GB0507601D0 (en) 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507602D0 (en) 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507680D0 (en) 2005-04-15 2005-05-25 Glaxo Group Ltd Compounds
JP5068747B2 (ja) 2005-06-14 2012-11-07 グラクソ グループ リミテッド ドーパミンｄ３受容体のモジュレーターとしてのアザビシクロ［３．１．０］ヘキサン誘導体
WO2007013936A2 (en) * 2005-07-21 2007-02-01 Wyeth Method for treating nervous system disorders and conditions
ATE487715T1 (de) 2005-08-22 2010-11-15 Glaxo Group Ltd Triazolderivate als modulatoren von dopamin-d3- rezeptoren
GB0517193D0 (en) 2005-08-22 2005-09-28 Glaxo Group Ltd Novel use
GB0517187D0 (en) 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517191D0 (en) 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
EA200870404A1 (ru) 2006-04-03 2009-04-28 Глэксо Груп Лимитед Производные азабицикло[3.1.0.]гексила в качестве модуляторов рецепторов допамина d3
GB0616574D0 (en) 2006-08-21 2006-09-27 Glaxo Group Ltd Compounds
DE102006035468A1 (de) * 2006-11-29 2008-06-05 Dilo Trading Ag Modifizierte Elektroden für elektrische Energiespeicher

Also Published As

Publication number Publication date
JP2009504793A (ja) 2009-02-05
WO2007022935A1 (en) 2007-03-01
ATE420859T1 (de) 2009-01-15
GB0517175D0 (en) 2005-09-28
EP1917242B1 (en) 2009-01-14
US7776904B2 (en) 2010-08-17
DE602006004882D1 (de) 2009-03-05
US20090030062A1 (en) 2009-01-29
JP5084731B2 (ja) 2012-11-28
EP1917242A1 (en) 2008-05-07

Similar Documents

Publication Publication Date Title
ES2337590T3 (es) Derivados de azabiciclo (3.1.0) hexano utiles como moduladores de los receptores d3 de dopamina.
ES2327162T3 (es) Derivados de azabicilo(3,1,0)hexano utiles como moduladores de los receptores de dopamina d3.
TW201742863A (zh) 靶向蛋白質之嵌合化合物、組合物、方法及其用途
CN120981228A (zh) 化合物、组合物和方法
EA016126B1 (ru) Антагонисты неосновного рецептора-1 меланинконцентрирующего гормона
KR102679517B1 (ko) Tnf 알파의 조정제로서 유용한 시클릭 화합물
ES2358445T3 (es) Derivados de azabiciclo (3.1.0) hexano útiles como moduladores de los receptores d3 de dopamina.
US7776904B2 (en) Azabicyclo [3.1.0] hexylphenyl derivatives as modulators of dopamine D3 receptors
CN110234638A (zh) 杂芳基苯氧基苯甲酰胺kappa阿片类配体
ES2339274T3 (es) 3-triazoliltioalquil-3-azabiciclo(3-1-o)hexanos y su uso como ligandospara los receptores d3 de dopamina.
ES2241752T3 (es) Derivados de azabicicloalcanos para usar como inhibidores de la recaptacion de serotonina y antagonistas de 5ht2a.
CA2871453A1 (en) Quinazolinedione derivative
ES3009813T3 (en) Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists
CN120882411A (zh) 化合物、组合物和方法
ES2353906T3 (es) Nuevos compuestos.
JP7623294B2 (ja) 化合物、組成物および方法
JP2008543801A (ja) ドーパミンｄ３受容体のモジュレーターとしてのアザビシクロ［３．１．０］ヘキサン誘導体
ES2839407T3 (es) Antagonistas del receptor de dopamina D3 que tienen una unidad estructural morfolina
ES2321217T3 (es) Inhibidores del transporte de glicina.
ES2378861T3 (es) Derivados de azabiciclo[3.1.0]hexilo como moduladores de los receptores D3 de la dopamina
CA3106438A1 (en) Compounds and compositions for the treatment of cystic fibrosis
ES2371147T3 (es) Derivados de azabiciclo[3.1.0]hexano útiles como moduladores de los receptores d3 de dopamina.
CN105899506A (zh) 作为RORc调节剂的杂芳基磺内酰胺衍生物
ES2356843T3 (es) Derivados de triazol como moduladores de los receptores d3 de dopamina.
ES2361201T3 (es) Derivados de azabiciclo[3.1.0]hexano como moduladores de los receptores d3 de dopamina.